{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:51:55Z","timestamp":1786485115446,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/mol.0b013e328235a5a2","type":"journal-article","created":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T08:03:32Z","timestamp":1184054612000},"page":"409-414","source":"Crossref","is-referenced-by-count":41,"title":["Pharmacogenomics of statin response"],"prefix":"10.1097","volume":"18","author":[{"given":"Lara M","family":"Mangravite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210205","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R2-6-20210205","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R3-6-20210205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R4-6-20210205","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1001\/jama.283.22.2935","article-title":"Statins and risk of coronary heart disease","volume":"283","author":"LaRosa","year":"2000","journal-title":"JAMA"},{"key":"R5-6-20210205","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-6-20210205","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s10038-006-0025-1","article-title":"Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy","volume":"51","author":"Takane","year":"2006","journal-title":"J Hum Genet"},{"key":"R7-6-20210205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1074248406293732","article-title":"The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate","volume":"11","author":"Christidis","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R8-6-20210205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2143\/AC.61.3.2014836","article-title":"Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)","volume":"61","author":"Maitland-van der Zee","year":"2006","journal-title":"Acta Cardiol"},{"key":"R9-6-20210205","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","article-title":"Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin","volume":"55","author":"Zuccaro","year":"2007","journal-title":"Pharmacol Res"},{"key":"R10-6-20210205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1463-1326.2006.00577.x","article-title":"Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus","volume":"9","author":"Tavintharan","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R11-6-20210205","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.tpj.6500402","article-title":"Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts","volume":"7","author":"Goodarzi","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"R12-6-20210205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2796.2006.01674.x","article-title":"Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin","volume":"260","author":"Marschang","year":"2006","journal-title":"J Intern Med"},{"key":"R13-6-20210205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2006.10.019","article-title":"Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study","volume":"153","author":"Maitland-van der Zee","year":"2007","journal-title":"Am Heart J"},{"key":"R15-6-20210205","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.freeradbiomed.2006.04.026","article-title":"eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite","volume":"41","author":"Nagassaki","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"R16-6-20210205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijcard.2005.10.024","article-title":"Interleukin-6 (IL-6)-174 G\/C polymorphism\u2013lack of association with inflammatory and haemostatic variables in patients with coronary heart disease treated with atorvastatin and quinapril","volume":"112","author":"Potaczek","year":"2006","journal-title":"Int J Cardiol"},{"key":"R17-6-20210205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.mbc.0000198052.65505.00","article-title":"Interleukin-6-174 G\/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients","volume":"17","author":"Potaczek","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R18-6-20210205","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1538-7836.2006.02031.x","article-title":"The 4G\/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin","volume":"4","author":"Roncal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R19-6-20210205","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R20-6-20210205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clpt.2006.01.010","article-title":"Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin","volume":"79","author":"Igel","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R21-6-20210205","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2006.02643.x","article-title":"Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes","volume":"61","author":"Hedman","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R22-6-20210205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clpt.2006.01.011","article-title":"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril","volume":"79","author":"Maeda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R23-6-20210205","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R24-6-20210205","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.fpc.0000230422.50962.91","article-title":"Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics","volume":"16","author":"Niemi","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R25-6-20210205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta"},{"key":"R26-6-20210205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0091270006295063","article-title":"Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects","volume":"47","author":"Kim","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R27-6-20210205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"R28-6-20210205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/sj.tpj.6500384","article-title":"Clinical implications of pharmacogenomics of statin treatment","volume":"6","author":"Mangravite","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"R29-6-20210205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.mol.0000137226.54278.60","article-title":"CETP gene variation: relation to lipid parameters and cardiovascular risk","volume":"15","author":"Boekholdt","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"R30-6-20210205","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"R31-6-20210205","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/01.mol.0000191913.16321.60","article-title":"Clinical implications for statin pleiotropy","volume":"16","author":"Liao","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"R32-6-20210205","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences","volume":"32","author":"Lennernas","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R33-6-20210205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2003.12.016","article-title":"Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics","volume":"75","author":"Mwinyi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R34-6-20210205","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R35-6-20210205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2133\/dmpk.19.375","article-title":"Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors","volume":"19","author":"Tachibana-Iimori","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"R36-6-20210205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.tpj.6500328","article-title":"An association study of 43 SNPs in 16 candidate genes with atorvastatin response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R37-6-20210205","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","article-title":"A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle","volume":"1","author":"Laaksonen","year":"2006","journal-title":"PLoS ONE"},{"key":"R38-6-20210205","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0b013e328235a5a2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:00:40Z","timestamp":1620964840000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-200708000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e328235a5a2","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}